Markets

Vertex stock jumps as rival cystic fibrosis drug fails trial

2 sources ·2 articles ·55m ago Vertex

2 outlets - including Biopharmadive and Investing - are covering this story. Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

Covered by 2 outlets

Biopharmadive 1 Investing 1

All coverage · 2 articles

BioPharma Dive ·55m ago

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

Investing.com Stock Market ·3h ago

Vertex stock jumps as rival cystic fibrosis drug fails trial

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex →

Vertex stock jumps as rival cystic fibrosis drug fails trial →

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Vertex stock jumps as rival cystic fibrosis drug fails trial